Stock VELO VELOXIS PHARMACEUTICALS A/S
Add to a list
To use this feature you must be a member
Log inSign up

Comparison Chart Veloxis Pharmaceuticals A/S

Equities

VELO

DK0060048148

Delayed Nasdaq Copenhagen
Other stock markets
 		5-day change 1st Jan Change
- DKK -.--% Intraday chart for Veloxis Pharmaceuticals A/S -.--% -0.50%
2022 Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) CI
2021 Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA. CI
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Compared values

Sector Change 5d. change 1st Jan change 1-year change 5-years change Capi. ST MT LT
VELOXIS PHARMACEUTICALS A/S
Specialty & Advanced Pharmaceuticals
-.--%-.--% - - - 1.64B - - -

Technical Rankings Surperformance

  1. Stock Market
  2. Equities
  3. VELO Stock
  4. Charts Veloxis Pharmaceuticals A/S
  5. Comparison Chart
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW